Tachycardia-induced cardiomyopathy: A review of literature

PACE - Pacing and Clinical Electrophysiology

Volumn 28, Issue 7, 2005, Pages 710-721

  Khasnis, Atul ^a   Jongnarangsin, Krit ^a   Abela, George ^a   Veerareddy, Srikar ^a   Reddy, Vivek ^b   Thakur, Ranjan ^a,c  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Ingham Regional Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; EXCITATION CONTRACTION COUPLING; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART PACING; HUMAN; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; SINUS RHYTHM; TACHYCARDIA INDUCED CARDIOMYOPATHY;

CARDIOMYOPATHIES; HEART; HUMANS; TACHYCARDIA;

EID: 22344436968     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2005.00143.x     Document Type: Review

References (102)

1. Gossage AM, Braxton Hicks JA. On auricular fibrillation. QJM 1913; 6:435-440.
2. Brill IC. Auricular fibrillation with congestive failure and no other evidence of organic heart disease. Am Heart J 1937; 13:175-182.
3. Whipple GH, Sheffield LT, Woodman EG, Theophilis C, Friedman S. Reversible congestive heart failure due to chronic rapid stimulation of the normal heart. Proc N Engl Cardiovasc Soc 1962; 20:39-40.
4. Ravens U, Davia K, Davies CH, O'Gara P, Drake-Holland AJ, Hynd JW, et al. Tachycardia-induced failure alters contractile properties of canine ventricular myocytes. Cardiovasc Res 1996; 32(3):613-621.
5. Quiniou G, Chevalier JM, Barbou F, Bire F, Clementy J. Tachycardia-induced cardiomyopathy, unusual and reversible cause of left ventricular dysfunction: Report of 9 cases. Ann Cardiol Angeiol (Paris) 2000; 49(5):301-308.
6. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 1997; 29(4):709-715.
7. McGuire MA, Lau KC, Davis LM, Knight P, Uther JB, Ross DL. Permanent junctional reciprocating tachycardia misdiagnosed as 'cardiomyopathy'. Aust N Z J Med 1991; 21(2):239-241.
8. Yu YH, Bilezikian JP. Tachycardia-induced cardiomyopathy secondary to thyrotoxicosis: A young man with previously unrecognized Graves' disease. Thyroid 2000; 10(10):923-927.
9. Chang-Chretien K, Chew JT, Judge DP. Reversible dilated cardiomyopathy associated with glucagonoma. Heart 2004; 90(7):e44.
10. Chugh SS, Shen WK, Luria DM, Smith HC. First evidence of premature ventricular complex-induced cardiomyopathy: A potentially reversible cause of heart failure. J Cardiovasc Electrophysiol 2000; 11(3):328-329.
11. Singh B, Sudan D, Kaul U. Radiofrequency ablation for bundle branch reentrant tachycardia in a patient with aortic valve replacement and left ventricular dysfunction. Indian Heart J 1998; 50(5):551-553.
12. Vijgen J, Hill P, Biblo LA, Carlson MD. Tachycardia-induced cardiomyopathy secondary to right ventricular outflow tract ventricular tachycardia: Improvement of left ventricular systolic function after radiofrequency catheter ablation of the arrhythmia. J Cardiovasc Electrophysiol 1997; 8(4):445-450.
13. Singh B, Kaul U, Talwar KK, Wasir HS. Reversibility of "tachycardia induced cardiomyopathy" following the cure of idiopathic left ventricular tachycardia using radiofrequency energy. Pacing Clin Electrophysiol 1996; 19(9):1391-1392.
14. Ott P, Kelly PA, Mann DE, Damle RS, Reiter MJ, Lindefeld J. Tachycardia-induced cardiomyopathy in a cardiac transplant recipient: Treatment with radiofrequency catheter ablation. J Cardiovasc Electrophysiol 1995; 6(5):391-395.
15. Wilson JR, Douglas P, Hickey WF, Lanoce V, Ferraro N, Muhammad A, Reichek N. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: Cardiac effects. Circulation 1987; 75(4):857-867.
16. Fuenmayor AJ, Fuenmayor AM. Tachycardiomyopathy in patients with and without subacute cardiac pathology. Experiences at the Cardiovascular Center of Merida, Venezuela. Arch Inst Cardiol Mex 1998; 68(6):515-520.
17. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 1; 92(7):1954-1968.
18. Zupan I, Rakovec P, Budihna N, Brecelj A, Kozelj M. Tachycardia induced cardiomyopathy in dogs; relation between chronic supraventricular and chronic ventricular tachycardia. Int J Cardiol 1996; 56(1):75-81.
19. Thackray SD, Witte KK, Nikitin NP, Clark AL, Kaye GC, Cleland JG. The prevalence of heart failure and asymptomatic left ventricular systolic dysfunction in a typical regional pacemaker population. Eur Heart J 2003; 24(12):1143-1152.
20. Byrne MJ, Raman JS, Alferness CA, Esler MD, Kaye DM, Power JM. An ovine model of tachycardia-induced degenerative dilated cardiomyopathy and heart failure with prolonged onset. J Card Fail 2002; 8(2):108-115.
21. Moe GW, Howard RJ, Grima EA, Armstrong PW. How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure? J Card Fail 1995; 1(3):223-228.
22. Timek TA, Dagum P, Lai DT, Liang D, Daughters GT, Tibayan F, et al. Tachycardia-induced cardiomyopathy in the ovine heart: Mitral annular dynamic three-dimensional geometry. J Thorac Cardiovasc Surg 2003; 125(2):315-324.
23. Tibayan FA, Lai DT, Timek TA, Dagum P, Liang D, Daughters GT, et al. Alterations in left ventricular torsion in tachycardia-induced dilated cardiomyopathy. J Thorac Cardiovasc Surg 2002; 124(1):43-49.
24. Nakamura R, Egashira K, Machida Y, Hayashidani S, Takeya M, Utsumi H, et al. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: Roles of oxidative stress and inflammation. Circulation 2002; 106(3):362-367.
25. Tomita M, Ikeguchi S, Kagawa K, Noda T, Nishigaki K, Furuta S, Gotoh K, Fujiwara H. Serial histopathologic myocardial findings in a patient with ectopic atrial tachycardia-induced cardiomyopathy. J Cardiol 1997; 29(1):37-42.
26. Spinale FG, Holzgrefe HH, Mukherjee R, Arthur SR, Child MJ, Powell JR. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol 1995; 268(2 Pt 2):H836-H847.
27. Yamamoto K, Burnett JC Jr, Meyer LM, Sinclair L, Stevens TL, Redfield MM. Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. Am J Physiol 1996; 271(6 Pt 2):R1529-R1534.
28. Tomita M, Spinale FG, Crawford FA, Zile MR. Changes in left ventricular volume, mass, and function during the development and regression of supraventricular tachycardia-induced cardiomyopathy. Disparity between recovery of systolic versus diastolic function. Circulation 1991; 83(2):635-644.
29. Moe GW, Grima EA, Howard RJ, Seth R, Armstrong PW. Left ventricular remodelling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure. Cardiovasc Res 1994; 28(1):66-71.
30. Jovanovic S, Grantham AJ, Tarara JE, Burnett JC Jr, Jovanovic A, Terzic A. Increased number of cardiomyocytes in cross-sections from tachycardia-induced cardiomyopathic hearts. Int J Mol Med 1999; 3(2):153-155.
31. Spinale FG, Grine RC, Tempel GE, Crawford FA, Zile MR. Alterations in the myocardial capillary vasculature accompany tachycardia-induced cardiomyopathy. Basic Res Cardiol 1992; 87(1):65-79.
32. Spinale FG, Tanaka R, Crawford FA, Zile MR. Changes in myocardial blood flow during development of and recovery from tachycardia-induced cardiomyopathy. Circulation 1992; 85(2):717-729.
33. O'Brien PJ, O'Grady M, McCutcheon LJ, Shen H, Nowack L, Horne RD. Myocardial myoglobin deficiency in various animal models of congestive heart failure. J Mol Cell Cardiol 1992; 24(7):721-730.
34. Moe GW, Canepa-Anson R, Armstrong PW. Atrial natriuretic factor: Pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. J Cardiovasc Pharmacol 1992; 19(5):691-700.
35. Moe GW, Grima EA, Wong NL, Howard RJ, Armstrong PW. Dual natriuretic peptide system in experimental heart failure. J Am Coll Cardiol 1993; 22(3):891-898.
36. Moe GW, Angus C, Howard RJ, De Bold AJ, Armstrong PW. Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure. Cardiovasc Res 1990; 24(7):570-577.
37. Moe GW, Grima EA, Angus C, Wong NL, Hu DC, Howard RJ, Armstrong PW. Response of atrial natriuretic factor to acute and chronic increases of atrial pressures in experimental heart failure in dogs. Role of changes in heart rate, atrial dimension, and cardiac tissue concentration. Circulation 1991; 83(5):1780-1787.
38. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz 2000; 25:299-306.
39. Grima EA, Moe GW, Howard RJ, Armstrong PW. Recovery of attenuated baroreflex sensitivity in conscious dogs after reversal of pacing induced heart failure. Cardiovasc Res 1994; 28(3):384-390.
40. Shite J, Qin F, Mao W, Kawai H, Stevens SY, Liang C. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardia-induced cardiomyopathy. J Am Coll Cardiol 2001; 38(6):1734-1740.
41. Jovanovic S, Granthani AJ, Tarara JE, Burnett JC Jr, Jovanovic A, Terzic A. Increased number of cardiomyocytes in cross-sections from tachycardia-induced cardiomyopathic hearts. Int J Mol Med 1999; 3(2):153-155.
42. Parker AB, Azevedo ER, Baird MG, Smith SJ, Arnold JM, Humen DP, et al. ARCTIC: Assessment of haemodynamic response in patients with congestive heart failure to telmisartan: A multicentre dose-ranging study in Canada. Am Heart J 1999; 138(5 Pt 1):843-848.
43. Marin-Garcia J, Goldenthal MJ, Moe GW. Selective endothelin receptor blockade reverses mitochondrial dysfunction in canine heart failure. J Card Fail 2002; 8(5):326-332.
44. Moe GW, Albernaz A, Naik GO, Kirchengast M, Stewart DJ. Beneficial effects of long-term selective endothelin type A receptor blockade in canine experimental heart failure. Cardiovasc Res 1998; 39(3):571-579.
45. Dupuis J, Moe GW, Cernacek P. Reduced pulmonary metabolism of endothelin-1 in canine tachycardia-induced heart failure. Cardiovasc Res 1998; 39(3):609-616.
46. Mukherjee R, Hewett KW, Spinale FG. Myocyte electrophysiological properties following the development of supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 1995; 27(6):1333-1348.
47. He J, Conklin MW, Foell JD, Wolff MR, Haworth RA, Coronado R, et al. Reduction in density of transverse tubules and L-type Ca(2+) channels in canine tachycardia-induced heart failure. Cardiovasc Res 2001; 49(2):298-307.
48. Zellner JL, Spinale FG, Eble DM, Hewett KW, Crawford FA Jr. Alterations in myocyte shape and basement membrane attachment with tachycardia-induced heart failure. Circ Res 1991; 69(3):590-600.
49. Tanaka R, Fulbright BM, Mukherjee R, Burchell SA, Crawford FA, Zile MR, et al. The cellular basis for the blunted response to beta-adrenergic stimulation in supraventricular tachycardia-induced cardiomyopathy. J Mol Cell Cardiol 1993; 25(10):1215-1233.
50. Spinale FG, Tempel GE, Mukherjee R, Eble DM, Brown R, Vacchiano CA, et al. Cellular and molecular alterations in the beta adrenergic system with cardiomyopathy induced by tachycardia. Cardiovasc Res 1994; 28(8):1243-1250.
51. Eble DM, Spinale FG. Contractile and cytoskeletal content, structure, and mRNA levels with tachycardia-induced cardiomyopathy. Am J Physiol 1995; 268(6 Pt 2):H2426-H2439.
52. Balijepalli RC, Lokuta AJ, Maertz NA, Buck JM, Haworth RA, Valdivia HH, et al. Depletion of T-tubules and specific subcellular changes in sarcolemmal proteins in tachycardia-induced heart failure. Cardiovasc Res 2003; 59(1):67-77.
53. Takahashi M, Tsutsui H, Kinugawa S, Igarashi-Saito K, Yamamoto S, Yamamoto M, et al. Role of microtubules in the contractile dysfunction of myocytes from tachycardia-induced dilated cardiomyopathy. J Mol Cell Cardiol 1998; 30(5):1047-1057.
54. Heinke MY, Wheeler CH, Yan JX, Amin V, Chang D, Einstein R, et al. Changes in myocardial protein expression in pacing-induced canine heart failure. Electrophoresis 1999; 20(10):2086-2093.
55. Heinke MY, Yao M, Chang D, Einstein R, dos Remedios CG. Apoptosis of ventricular and atrial myocytes from pacing-induced canine heart failure. Cardiovasc Res 2001; 49(1):127-134.
56. Lacroix D, Gluais P, Marquie C, D'Hoinne C, Adamantidis M, Bastide M. Repolarization abnormalities and their arrhythmogenic consequences in porcine tachycardia-induced cardiomyopathy. Cardiovasc Res 2002; 54(1):42-50.
57. Kohl P, Kamkin AG, Kiseleva IS, Noble D. Mechanosensitive fibroblasts in the sino-atrial node region of rat heart: Interaction with cardiomyocytes and possible role. Exp Physiol 1994; 79(6):943-956.
58. Pak PH, Nuss HB, Tunin RS, Kaab S, Tomaselli GF, Marban E, et al. Repolarization abnormalities, arrhythmia and sudden death in canine tachycardia-induced cardiomyopathy. J Am Coll Cardiol 1997; 30(2):576-584.
59. Clemo HF, Stambler BS, Baumgarten CM. Swelling-activated chloride current is persistently activated in ventricular myocytes from dogs with tachycardia-induced congestive heart failure. Circ Res 1999; 84(2):157-165.
60. Han W, Chartier D, Li D, Nattel S. Ionic remodeling of cardiac Purkinje cells by congestive heart failure. Circulation 2001; 104(17):2095-2100.
61. Han W, Zhang L, Schram G, Nattel S. Properties of potassium currents in Purkinje cells of failing human hearts. Am J Physiol Heart Circ Physiol 2002; 283(6):H2495-H2503.
62. Kaab S, Nuss HB, Chiamvimonvat N, O'Rourke B, Pak PH, Kass DA. Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res 1996; 78(2):262-273.
63. Spinale FG, Zellner JL, Johnson WS, Eble DM, Munyer PD. Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: Changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol 1996; 28(8):1591-1608.
64. Moe GW, Armstrong P. Pacing-induced heart failure: A model to study the mechanism of disease progression and novel therapy in heart failure. Cardiovasc Res 1999; 42(3):591-599.
65. Thorburn J, Xu S, Thorburn A. MAP kinase- and Rho-dependent signals interact to regulate gene expression but not actin morphology in cardiac muscle cells. EMBO J 1997; 16(8):1888-1900.
66. Spinale FG, Fulbright BM, Mukherjee R, Tanaka R, Hu J, Crawford FA, et al. Relation between ventricular and myocyte function with tachycardia-induced cardiomyopathy. Circ Res 1992; 71(1):174-187.
67. Wu Y, Bell SP, Trombitas K, Witt CC, Labeit S, LeWinter MM, Granzier H. Changes in titin isoform expression in pacing-induced cardiac failure give rise to increased passive muscle stiffness. Circulation 2002; 106(11):1384-1389.
68. Warren CM, Jordan MC, Roos KP, Krzesinski PR, Greaser ML. Titin isoform expression in normal and hypertensive myocardium. Cardiovasc Res 2003; 59(1):86-94.
69. Neagoe C, Kulke M, del Monte F, Gwathmey JK, de Tombe PP, Hajjar RJ, Linke WA. Titin isoform switch in ischemic human heart disease. Circulation 2002; 106(11):1333-1341.
70. Sen L, Cui G, Fonarow GC, Laks H. Differences in mechanisms of SR dysfunction in ischemic vs. idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2000; 279(2):H709-H718.
71. Saavedra WF, Paolocci N, St John ME, Skaf MW, Stewart GC, Xie JS, et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 2002; 90(3):297-304.
72. Lass A, Suessenbacher A, Wolkart G, Mayer B, Brunner F. Functional and analytical evidence for scavenging of oxygen radicals by L-arginine. Mol Pharmacol 2002; 61(5):1081-1088.
73. Qin F, Shite J, Mao W, Liang CS. Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: Association with improvement of cardiac function. Eur J Pharmacol 2003; 461(2-3):149-158.
74. Gupta M, Singal PK. Higher antioxidative capacity during a chronic stable heart hypertrophy. Circ Res 1989; 64(2):398-406.
75. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, Hernandez-Lopez E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996; 131(1):146-152.
76. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998; 31(6):1352-1356.
77. Moe GW, Naik G, Konig A, Lu X, Feng Q. Early and persistent activation of myocardial apoptosis, bax and caspases: Insights into mechanisms of progression of heart failure. Pathophysiology 2002; 8(3):183-192.
78. Schotten U, Greiser M, Benke D, Buerkel K, Ehrenteidt B, Stellbrink C, et al. Atrial fibrillation-induced atrial contractile dysfunction: A tachycardiomyopathy of a different sort. Cardiovasc Res 2002; 53(1):192-201.
79. Sun H, Chartier D, Leblanc N, Nattel S. Intracellular calcium changes and tachycardia-induced contractile dysfunction in canine atrial myocytes. Cardiovasc Res 2001; 49(4):751-761.
80. Li D, Melnyk P, Feng J, Wang Z, Petrecca K, Shrier A. Effects of experimental heart failure on atrial cellular and ionic electrophysiology. Circulation 2000; 101(22):2631-2638.
81. Li D, Shinagawa K, Pang L, Leung TK, Cardin S, Wang Z, Nattel S. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 2001; 104(21):2608-2614.
82. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54(2):456-461.
83. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc Res 2003; 60(2):315-325.
84. Shinagawa K, Shi YF, Tardif JC, Leung TK, Nattel S. Dynamic nature of atrial fibrillation substrate during development and reversal of heart failure in dogs. Circulation 2002; 105(22):2672-2678.
85. Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004; 63(2):236-244.
86. Cha TJ, Ehrlich JR, Zhang L, Shi YF, Tardif JC, Leung TK, Nattel S. Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation 2004; 109(3):412-418.
87. Eronen M. Outcome of fetuses with heart disease diagnosed in utero. Arch Dis Child Fetal Neonatal Ed 1997; 77(1):F41-F46.
88. Van den Berg MP, Tuinenburg AE, Crijns HJ, Van Gelder IC, Gosselink AT, Lie KI. Heart failure and atrial fibrillation: Current concepts and controversies. Heart 1997; 77:309-313.
89. Ozcan C, Jahangir A, Friedman PA, Munger TM, Packer DL, Hodge DO, et al. Significant effects of atrioventricular node ablation and pacemaker implantation on left ventricular function and long-term survival in patients with atrial fibrillation and left ventricular dysfunction. Am J Cardiol 2003; 92(1):33-37.
90. Wood MA, Kay GN, Ellenbogen KA, The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation. Europace 1999; 1(1):22-25.
91. Weerasooriya R, Davis M, Powell A, Szili-Torok T, Shah C, Whalley D. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003; 41(10):1697-1702.
92. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens. J Am Coll Cardiol 1999; 33(2):304-310.
93. Azpitarte J, Baum O, Moreno E, Garcia-Orta R, Sanchez-Ramos J, Tercedor L. In patients with chronic atrial fibrillation and left ventricular systolic dysfunction, restoration of sinus rhythm confers substantial benefit. Chest 2001; 120(1):132-138.
94. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Yschron EB, et al. AFFIRM investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347(23):1825-1833.
95. Mitchell AR, Spurrell PA, Ahmet H, Higson M, Sulke N. Reversal of tachycardiomyopathy by the atrial defibrillator. Eur J Heart Fail 2002; 4(4):485-488.
96. Chen RP, Ignaszewski AP, Robertson MA. Successful treatment of supraventricular tachycardia-induced cardiomyopathy with amiodarone: Case report and review of literature. Can J Cardiol 1995; 11(10):918-922.
97. Krapp M, Baschat AA, Gembruch U, Geipel A, Germer U. Fiecainide in the intrauterine treatment of fetal supraventricular tachycardia. Ultrasound Obstet Gynecol 2002; 19(2):158-164.
98. Kim YH, Goldberger J, Kadish A. Treatment of ventricular tachycardia-induced cardiomyopathy by transcatheter radiofrequency ablation. Heart 1996; 76(6):550-552.
99. Suzuki Y, Tanaka M, Sohmiya M, Yoshida T, Okamoto K. Antioxidant properties of carvedilol: Inhibition of lipid peroxidation, protein oxidation and superoxide generation. Neurol Res 2003; 25(7):749-753.
100. Zhang S, Sun Z, Liu L, Hasichaonu. Carvedilol attenuates CPB-induced apoptosis in dog heart: Regulation of Fas/FasL and caspase-3 pathway. Chin Med J (Engl) 2003; 116(5):761-766.
101. Yuan Z, Shioji K, Kihara Y, Takenaka H, Onozawa Y, Kishimoto C, et al. Cardioprotective effects of carvedilol on acute autoimmune myocarditis: Anti-inflammatory effects associated with antioxidant property. Am J Physiol Heart Circ Physiol 2004; 286(1):H83-H90.
102. Chin BS, Langford NJ, Nuttall SL, Gibbs CR, Blann AD, Lip GY. Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure. Eur J Heart Fail 2003; 5(2):171-174.